Basic information
Biomarker: MSI
Biomarker subtype: gene
Clinical application: prognosis(unfavorable)
Histology type: endometrioid endometrial carcinoma
Stage: high risk
Cohort characteristics
Country: Spain
Region: de Gran Canaria
Study type: retrospective study
Followed up time : median clinical follow-up 138 months,with a maximum of 232 months
Cohort age: 64.63
Protocol age: 66.2
Control age: 64.21
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
| 93 | EEC | 93 |
Sample information
Sample type : tissue
Clinical method: PCR
Expression pattern : BAT-25, BAT-26, NR21, NR24, and NR27
Disease information
Statictics: Mean
Cohort age: 64.63
Protocol age: 66.2
Control age: 64.21
Related information
Description: These results suggest that MSI may predict radiotherapy response in early-stage EEC.
